Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CLINICAL PHARMACOKINETICS OF ESCALATING IV DOSES OF DEXANABINOL (HU-211), A NEUROPROTECTANT AGENT, IN NORMAL VOLUNTEERS
Autore:
BREWSTER ME; POP E; FOLTZ RL; REUSCHEL S; GRIFFITH W; AMSELEM S; BIEGON A;
Indirizzi:
PHARMOS LTD,KIRYAT WEIZMANN IL-76326 REHOVOT ISRAEL PHARMOS LTD,KIRYAT WEIZMANN IL-76326 REHOVOT ISRAEL PHARMOS CORP ALACHUA FL 00000 NW TOXICOL INC,BIOANALYT DIV SALT LAKE CITY UT 00000 PHARMAKOPIUS INT READING BERKS ENGLAND
Titolo Testata:
International journal of clinical pharmacology and therapeutics
fascicolo: 9, volume: 35, anno: 1997,
pagine: 361 - 365
SICI:
0946-1965(1997)35:9<361:CPOEID>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
HEAD-INJURY; CANNABINOIDS; ANTAGONIST; DOGS; RAT;
Keywords:
DEXANABINOL (HU-211); CANNABINOIDS; NEUROPROTECTANT; HUMAN; PHARMACOKINETICS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
17
Recensione:
Indirizzi per estratti:
Citazione:
M.E. Brewster et al., "CLINICAL PHARMACOKINETICS OF ESCALATING IV DOSES OF DEXANABINOL (HU-211), A NEUROPROTECTANT AGENT, IN NORMAL VOLUNTEERS", International journal of clinical pharmacology and therapeutics, 35(9), 1997, pp. 361-365

Abstract

The pharmacokinetics of dexanabinol (HU-211), a synthetic, nonpsychotropic cannabinoid with neuroprotectant action, was evaluated in a phase I clinical trial. The compound was administered at doses of 48 mg, 100 mg, and 200 mg as short i.v. infusions in a Cremophor-ethanol vehicle diluted with saline. All administrations were well-tolerated and nocompound-related side-effects were observed. Plasma concentrations ofdexanabinol were quantitated using a GC/MS/MS technique which provided a limit of quantitation of 100 pg/ml. The elimination of dexanabinolwas best fitted to a 3-compartment model with a rapid distribution half-life (< 5 min), an intermediate phase half-life of approximately 90min, and a slow terminal elimination half-life (similar to 9 h). The pharmacokinetics were linear over the evaluated dose range. The plasmaclearance of the drug was high (1,700 ml/min) and the volume of distribution approximately 151/kg. These data are similar to those reportedfor naturally occurring cannabinoids such as Delta(9)-tetrahydrocannabinol and cannabidiol.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/09/20 alle ore 02:43:28